# SAMHD1

## Overview
SAMHD1 is a human gene that encodes the protein SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1, a key regulator of intracellular deoxynucleotide triphosphate (dNTP) pools. This protein is characterized by its dual-domain structure, comprising a sterile alpha motif (SAM) domain and an HD phosphohydrolase domain, which together facilitate its function as a deoxynucleoside triphosphate triphosphohydrolase. SAMHD1 plays a crucial role in maintaining genomic stability by hydrolyzing dNTPs, thereby regulating DNA replication and repair processes. It is also involved in immune regulation and acts as a restriction factor against retroviral infections, such as HIV-1, by limiting the availability of dNTPs necessary for viral replication (Kretschmer2014SAMHD1; Schott2021SAMHD1). Mutations in the SAMHD1 gene are linked to various clinical conditions, including Aicardi-Goutières syndrome and certain cancers, highlighting its significance in both health and disease (Zhang2020Involvement; Schott2021SAMHD1).

## Structure
The SAMHD1 protein is a 626-residue human protein characterized by two major structural domains: the N-terminal sterile alpha motif (SAM) domain and the HD phosphohydrolase domain. The SAM domain functions as a helical scaffold for protein or nucleic acid binding, while the HD domain contains the active site responsible for dNTP hydrolysis (Morris2020Crystal). The protein's quaternary structure is a tetramer, which is crucial for its enzymatic activity. This tetrameric form is stabilized by sequences at the N and C termini of the HD domain and is activated by the binding of dGTP at allosteric sites, which induces conformational changes enhancing substrate interaction (Zhu2013Structural; Morris2020Crystal).

The active site of SAMHD1 features a bi-metallic Fe-Mg center, which positions a hydroxide nucleophile for the hydrolysis of dNTPs. This center is a novel finding for SAMHD1 but is similar to other HD domains involved in phosphoryl transfer reactions (Morris2020Crystal). The protein's structure also includes specific residues, such as Arg164, His210, and His215, which are involved in substrate binding and catalysis (Morris2020Crystal). The tetrameric structure is essential for SAMHD1's role in restricting HIV-1 and regulating LINE-1 retrotransposition (Zhu2013Structural).

## Function
SAMHD1, or Sterile Alpha Motif and Histidine/Aspartic Acid Domain-Containing Protein 1, is a crucial regulator of the intracellular deoxynucleotide triphosphate (dNTP) pool in human cells. It functions as a deoxynucleoside triphosphate triphosphohydrolase, hydrolyzing dNTPs into deoxynucleosides and inorganic triphosphate, which is essential for maintaining genomic stability and regulating DNA replication and repair (Kretschmer2014SAMHD1; Felip2022Modulation). SAMHD1 is active in both the nucleus and cytoplasm, where it plays a significant role in DNA metabolism and immune regulation (Schott2021SAMHD1).

In healthy human cells, SAMHD1 helps prevent genomic instability by maintaining a balanced dNTP pool, which is necessary for accurate DNA replication and repair processes (Zhang2020Involvement). It is involved in the DNA damage response, particularly in the repair of DNA double-strand breaks through homologous recombination, promoting DNA end resection and recruiting interacting proteins to damage sites (Zhang2020Involvement). SAMHD1 also acts as a negative regulator of innate immunity by controlling inflammatory signals and interacting with the NF-κB pathway, which is important for preventing chronic inflammation (Schott2021SAMHD1). Additionally, SAMHD1 restricts retroviral infections, such as HIV-1, by reducing intracellular dNTP levels, thereby inhibiting viral reverse transcription (Zhang2020Involvement).

## Clinical Significance
Mutations and altered expression of the SAMHD1 gene have significant clinical implications. SAMHD1 mutations are associated with Aicardi-Goutières syndrome (AGS), a condition characterized by chronic inflammation and increased mutation frequencies due to nucleotide metabolism disorders (Zhang2020Involvement; Schott2021SAMHD1). These mutations can lead to genomic instability by disrupting the balance of deoxynucleotide triphosphate (dNTP) pools, contributing to oncogenic transformation and cancer development (Schott2021SAMHD1).

In cancer, SAMHD1 is often downregulated, particularly in lung cancers, correlating with cancer progression (Schott2021SAMHD1). Its expression levels influence prognosis and treatment efficacy in various cancers, including breast, ovarian, and non-small cell lung cancer (NSCLC). Low SAMHD1 expression is linked to better prognosis and treatment response in these cancers (Felip2022Modulation). Conversely, high SAMHD1 expression is associated with poorer prognostic outcomes and increased resistance to certain chemotherapeutic agents, such as cytarabine in mantle cell lymphoma (MCL) (Wang2021SAMHD1).

SAMHD1 also plays a role in immune regulation, where its mutations can lead to the accumulation of self-derived nucleic acids, triggering type I interferon-mediated responses and promoting tumor-related inflammation (Schott2021SAMHD1). These interactions highlight SAMHD1's clinical significance in cancer, autoimmune diseases, and viral infections.

## Interactions
SAMHD1 interacts with various proteins and nucleic acids, playing a significant role in its biological functions. It binds RNA through its HD domain, with specific N-terminal and C-terminal regions necessary for this interaction. This RNA binding is independent of SAMHD1's cellular localization and contributes to its retroviral restriction capabilities (White2013Contribution). SAMHD1 also interacts with the eukaryotic elongation factor eEF1A1, primarily through its HD domain. This interaction is confirmed by yeast two-hybrid assays and co-immunoprecipitation experiments, suggesting a role in SAMHD1's regulation and potential degradation via the proteasome (Morrissey2015The).

SAMHD1's interaction with nucleic acids extends to oligonucleotides, which can bind at its allosteric sites. This binding is enhanced by phosphorothioate linkages and affects SAMHD1's dNTPase activity by stabilizing it in an inactive dimeric state, thus inhibiting its enzymatic function (Yu2021Nucleic). The protein's ability to form oligomers is crucial for its function, with the HD domain playing a key role in oligomerization and enzymatic activity (White2013Contribution). These interactions highlight SAMHD1's multifaceted role in cellular processes, including viral restriction and nucleotide metabolism.


## References


[1. (Kretschmer2014SAMHD1) Stefanie Kretschmer, Christine Wolf, Nadja König, Wolfgang Staroske, Jochen Guck, Martin Häusler, Hella Luksch, Laura A Nguyen, Baek Kim, Dimitra Alexopoulou, Andreas Dahl, Alexander Rapp, M Cristina Cardoso, Anna Shevchenko, and Min Ae Lee-Kirsch. Samhd1 prevents autoimmunity by maintaining genome stability. Annals of the Rheumatic Diseases, 74(3):e17–e17, January 2014. URL: http://dx.doi.org/10.1136/annrheumdis-2013-204845, doi:10.1136/annrheumdis-2013-204845. This article has 129 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1136/annrheumdis-2013-204845)

[2. (Schott2021SAMHD1) Kerstin Schott, Catharina Majer, Alla Bulashevska, Liam Childs, Mirko H. H. Schmidt, Krishnaraj Rajalingam, Markus Munder, and Renate König. Samhd1 in cancer: curse or cure? Journal of Molecular Medicine, 100(3):351–372, September 2021. URL: http://dx.doi.org/10.1007/s00109-021-02131-w, doi:10.1007/s00109-021-02131-w. This article has 18 citations.](https://doi.org/10.1007/s00109-021-02131-w)

[3. (White2013Contribution) Tommy E. White, Alberto Brandariz-Nuñez, Jose Carlos Valle-Casuso, Sarah Amie, Laura Nguyen, Baek Kim, Jurgen Brojatsch, and Felipe Diaz-Griffero. Contribution of sam and hd domains to retroviral restriction mediated by human samhd1. Virology, 436(1):81–90, February 2013. URL: http://dx.doi.org/10.1016/j.virol.2012.10.029, doi:10.1016/j.virol.2012.10.029. This article has 115 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.virol.2012.10.029)

[4. (Morrissey2015The) Catherine Morrissey, David Schwefel, Valerie Ennis-Adeniran, Ian A. Taylor, Yanick J. Crow, and Michelle Webb. The eukaryotic elongation factor eef1a1 interacts with samhd1. Biochemical Journal, 466(1):69–76, February 2015. URL: http://dx.doi.org/10.1042/bj20140203, doi:10.1042/bj20140203. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20140203)

[5. (Morris2020Crystal) Elizabeth R. Morris, Sarah J. Caswell, Simone Kunzelmann, Laurence H. Arnold, Andrew G. Purkiss, Geoff Kelly, and Ian A. Taylor. Crystal structures of samhd1 inhibitor complexes reveal the mechanism of water-mediated dntp hydrolysis. Nature Communications, June 2020. URL: http://dx.doi.org/10.1038/s41467-020-16983-2, doi:10.1038/s41467-020-16983-2. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-16983-2)

[6. (Wang2021SAMHD1) Tao Wang, Wenqin Yue, Gusheng Tang, Mingyu Ye, Jiechen Yu, Bin Liu, Lijuan Jiao, Xuefei Liu, Shuyi Yin, Jie Chen, Lei Gao, Jianmin Yang, and Miaoxia He. Samhd1 mutations and expression in mantle cell lymphoma patients. Frontiers in Oncology, December 2021. URL: http://dx.doi.org/10.3389/fonc.2021.763151, doi:10.3389/fonc.2021.763151. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.763151)

[7. (Yu2021Nucleic) Corey H. Yu, Akash Bhattacharya, Mirjana Persaud, Alexander B. Taylor, Zhonghua Wang, Angel Bulnes-Ramos, Joella Xu, Anastasia Selyutina, Alicia Martinez-Lopez, Kristin Cano, Borries Demeler, Baek Kim, Stephen C. Hardies, Felipe Diaz-Griffero, and Dmitri N. Ivanov. Nucleic acid binding by samhd1 contributes to the antiretroviral activity and is enhanced by the gpsn modification. Nature Communications, February 2021. URL: http://dx.doi.org/10.1038/s41467-021-21023-8, doi:10.1038/s41467-021-21023-8. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-21023-8)

[8. (Felip2022Modulation) Eudald Felip, Lucía Gutiérrez-Chamorro, Maica Gómez, Edurne Garcia-Vidal, Margarita Romeo, Teresa Morán, Laura Layos, Laia Pérez-Roca, Eva Riveira-Muñoz, Bonaventura Clotet, Pedro Luis Fernandez, Ricard Mesía, Anna Martínez-Cardús, Ester Ballana, and Mireia Margelí. Modulation of dna damage response by sam and hd domain containing deoxynucleoside triphosphate triphosphohydrolase (samhd1) determines prognosis and treatment efficacy in different solid tumor types. Cancers, 14(3):641, January 2022. URL: http://dx.doi.org/10.3390/cancers14030641, doi:10.3390/cancers14030641. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14030641)

[9. (Zhang2020Involvement) Zhou Zhang, Lixia Zheng, Yang Yu, Jinying Wu, Fan Yang, Yingxi Xu, Qiqiang Guo, Xuan Wu, Sunrun Cao, Liu Cao, and Xiaoyu Song. Involvement of samhd1 in dntp homeostasis and the maintenance of genomic integrity and oncotherapy (review). International Journal of Oncology, February 2020. URL: http://dx.doi.org/10.3892/ijo.2020.4988, doi:10.3892/ijo.2020.4988. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2020.4988)

[10. (Zhu2013Structural) Chunfeng Zhu, Wenying Gao, Ke Zhao, Xiaohong Qin, Yinjie Zhang, Xin Peng, Lei Zhang, Yuhui Dong, Wenyan Zhang, Peng Li, Wei Wei, Yong Gong, and Xiao-Fang Yu. Structural insight into dgtp-dependent activation of tetrameric samhd1 deoxynucleoside triphosphate triphosphohydrolase. Nature Communications, November 2013. URL: http://dx.doi.org/10.1038/ncomms3722, doi:10.1038/ncomms3722. This article has 97 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms3722)